Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is 1 of 4 different categories of chronic prostatitis classified by the National Institute of Health (NIH) and is different from the first and second types. CP/CPPS primarily presents with pain symptoms in the prostate region in the absence of any urinary tract infection for at least 3 months of a 6-month period.1 Aside from pain symptoms, CP/CPPS is often associated with negative cognitive, behavioral, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract and sexual dysfunction, and affects adult men worldwide.2–4
Based on a survey in China, the prevalence of CP/CPPS-like symptoms among Chinese men is 4.5%.5 Moreover, it is estimated that CP/CPPS comprises 90% of the prostatitis syndromes among patients.6
Pharmacological interventions are often prescribed for patients with CP/CPPS. Drugs commonly prescribed for CP/CPPS management include antibiotics, anti-inflammatories (NSAIDs), alpha-adrenergic blockers, and neuromodulatory drugs.7–11 Given its complex etiology and pathogenesis, CP/CPPS is still one of the least understood diseases in urology and can present a major challenge to health care providers due to its poor response to therapy. In 2004, Nickel et al found that it may be problematic to treat CP/CPPS with monotherapeutic strategies; multimodal treatment aimed at primary symptoms is necessary, and comorbidity must be taken into consideration.10,12,13
As a form of complementary treatment, acupuncture has been performed on patients with urinary diseases in Eastern nations for a long time but has been limited by the insufficient number of high-quality, well-designed randomized controlled trials (RCTs).14 The evidence level of evidence-based medicine is still low.1 In 2012, Posadzki et al conducted a systematic review focused on acupuncture for CP/CPPS15. According to this review, acupuncture's treatment of CP/CPPS is encouraging. However, as previously highlighted, the quantity and quality of trials included in the review hindered the researchers’ ability to reach a firm conclusion.15 In the past 2 years, studies have been published on some new RCTs that focused on acupuncture for CP/CPPS. Therefore, an overall systematic review should be conducted. We performed this systematic review to re-evaluate the efficacy and safety of acupuncture for treating CP/CPPS.
MATERIALS AND METHODS
This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement,16 and the protocol of this systematic review and meta-analysis has been registered on PROSPERO (http://http://www.crd.york.ac.uk/PROSPERO). The registration number is CRD42015027522.
Types of Studies
Only randomized controlled trials (RCTs) that evaluated the effects and/or safety data on acupuncture for CP/CPPS were included. For a trial to be included, it needed to contain adequacy randomization methods, eligibility diagnoses, eligibility outcome reports, and a description of statistical methods. The quality of studies was evaluated by professional assessors. We excluded articles focused on mechanisms and those without full text, animal trials, or reviews. There were no restrictions on language, publication date, or publication status.
Types of Participants
Participants diagnosed with CP/CPPS (category III as classified by the NIH) were considered. CP/CPPS was defined as urogenital pain, lower urinary tract symptoms with or without psychological issues, and sexual dysfunction over at least 3 out of the past 6 months in the absence of any urinary tract infection. Participants with acute bacterial prostatitis, a benign enlargement, prostate cancer, or other prostate diseases were excluded.
Types of Intervention
The following eligible comparisons were included: (a) acupuncture compared to Western drugs, (b) acupuncture supplementing Western drugs compared to the same Western drugs, and (c) acupuncture compared to sham/placebo acupuncture or a waiting group. Moreover, to meet the objective of this review, we focused on acupuncture that could be administered in a primary care setting, which included any type of penetrating acupuncture (i.e., acupuncture, electro-acupuncture, warm acupuncture, abdominal acupuncture, auricular acupuncture, etc.). We excluded trials evaluating the effectiveness of acupoints injection, needle-knife, and Chinese herbs, or acupuncture as a complement to the above interventions. Trials in which acupuncture was an adjunctive treatment combined with conventional Western medicine were included.
Types of Outcome Measures
The primary outcome was the changes in the total NIH-CPSI score after treatment.17,18
Secondary outcomes included changes in NIH-CPSI subscales, IPSS, and the global response rate. In addition, adverse events from interventions were recorded.
Data Sources and Searches
We used the review methods recommended in the handbook of the Cochrane Back Review Group. The following databases were searched from their inception until 30 November 2015: MEDLINE, EMBASE, CENTRAL, Web of Science, CBM, CNKI, Wang-Fang Database, JCRM, and CiNii. We also searched grey literature via Google Scholar and websites of the National Institute of Diabetes and Digestive and Kidney Diseases. The search terms related to acupuncture, chronic prostatitis, chronic pelvic pain syndrome, and randomized controlled trials. No language barriers were imposed.
(See Table 1, Supplemental Content, http://links.lww.com/MD/A772 which represents the strategy for searching in the PUBMED database).
Two reviewers (JW and JZ) scanned the titles and abstracts independently and according to the eligibility assessments, which is protocol for systematic reviews. The search results will be imported to EndNote X7 software (Thomson Reuters, New York, NY) if available. Furthermore, duplications will also be eliminated by EndNote X7 software. Any disagreements between reviewers were resolved through discussion; if no agreement could be reached, a third rater would make a decision (ZL).
Data Collection Process
Two independent reviewers (JW and JZ) extracted sample sizes, means, standard deviations, and percentages. For the purpose of this review, we extracted the change score of means and standard deviation, and when there was insufficient data in trial reports, we attempted to contact authors once a week (at least 3 times). If no one responded, we estimated data using the methods recommended in the Cochrane Handbook for Systematic Reviews of Interventions and using an imputed correlation coefficient of 0.5 (R = 0.5):
C, B, and F denote change, baseline, and final, respectively.19
We created a spreadsheet of data extraction according to Cochrane Consumers and Communication Review Group's data extraction template. A pilot collection (2 reviewers extracted the data of 3 randomized controlled trials independently, and once the procedure ended, data were checked by a third rater) was performed to examine and test the rule of collection. Any disagreements between reviewers were resolved through discussion; if no agreement could be reached, a third rater would make a decision (ZL).
The following data were extracted from each included trial: (a) characteristics of participants (nation, age, diagnosis); (b) types of treatments and control groups (for acupuncture, the acupuncture type, manipulation, duration, and frequency were recorded; for drugs, the type, dose, duration and frequency were noted); (c) outcome measures (the variety of scales as well as the global response rates); and (d) the follow-up period, if available.
Risk of Bias Assessment
We used the Cochrane Collaboration tool to evaluate the risk of bias for the RCTs included.20 Two reviewers (ZQ and JW) independently evaluated the adequacy of random sequence generation and allocation concealment, blinding of participants, outcome assessors, incomplete outcome data, selective reporting, and other biases.21 Any disagreements were discussed and resolved by a third author (ZL).
To assess the possibility of publication bias, a funnel plot of the included trials is generally produced, where asymmetry of the funnel plot means that unpublished, smaller trials with negative results may be affecting the results of the meta-analysis. However, in this review, the low number of trials prevented use of a funnel plot and assessment of publication bias.
The primary outcome (total NIH-CPSI score) was calculated by computing the mean difference (MD) with 95% confidence intervals (CI). For secondary outcomes, data on continuous variables (i.e., NIH-CPSI subscores or IPSS) were calculated by computing MD with 95% CI. Data on dichotomous variables (i.e., the global response rate) were measured using the risk ratio (RR) with 95% CI. We used Revman V.5.3.3 software to synthesize extracted data and conduct a meta-analysis. The included trials administered different types of acupuncture, which can potentially cause heterogeneity of the results. Thus, a random effect model was used during meta-analysis. The presence of heterogeneity was assessed with Cochrane's Q-test and quantified with the I 2 test. We accepted the potential heterogeneity when the P value was >0.1 in the X 2 test and the I 2 was <50%. In the case of heterogeneity, we attempted to identify and explore the heterogeneity using sensitivity analysis or subgroup analysis—if the quantity of included trials was available.
A total of 1054 studies were searched, in which 372 duplicates were omitted and the titles and abstracts of 682 studies remained to be reviewed. The remaining studies were excluded for the following reasons: 192 were non-RCTs, 57 were the experiences of experts, 84 were animal trials or mechanisms, and 128 did not meet our criteria of intervention. After scanning titles and abstracts, the full texts of the remaining 221 studies were examined in more detail. It appeared that 52 studies were excluded because they were not true RCTs, 105 studies were excluded because they included inappropriate interventions, 35 studies did not have clear diagnoses, which may have included participants with bacteria prostatitis or other prostate diseases. Twenty-two did not provide standard outcome measures. Therefore, a total of 7 studies were available for quantity and quality analysis in this review.22–28
See flow diagram, Figure 1.
Four trials were from Malaysia, Korea, and Turkey and were published in English,22–24,27 and 3 trials were from China and were published in Chinese.25,26,28 All 7 trials were single-centre, randomized controlled trials. Treatment sessions were from 4 weeks to 10 weeks. Three trials set the follow-up period from 18 weeks to 24 weeks.22,24,27
The included studies involved at total of 471 adult male participants, and 399 participants were included in meta-analysis.22–28 Three trials involving 231 participants indicated they only included type IIIB,22,27,28 and participants of type IIIA were excluded; another 4 trials involving 240 participants included III types whether they were A or B.
Two trials used electro-acupuncture (EA) as an intervention.22,23 Five trials used manual acupuncture (MA) as an intervention, in which 1 trial used MA plus medicine (levofloxacin) as an intervention.26 Based on the prior protocol we followed, we included trials comparing acupuncture with sham/placebo acupuncture, no treatment, or conventional Western drugs as the control group. Four trials used drugs in the control procedure.22,25,26,28 Four trials used penetrating acupuncture on nonacupuncture points.23,24,27,28
In all studies the primary outcome assessed was the difference in total NIH-CPSI score between baseline and study completion. Most trials did not provide the variety of decreasing scores but rather the data on baseline and endpoints—with the exception of 2 trials.22,24 Based on our protocol, we took advantage of the methods recommended in the Cochrane Handbook to calculate and evaluate the changed data from the data they provided. In addition, the global response rate, NIH-CPSI subscale score, and IPSS were provided as the secondary outcomes of some trials.22–24,26-28
(see Table 2 and 3, Supplemental Content, http://links.lww.com/MD/A772 which summarizes the parameters of included trials).
Risk of Bias Within Studies
Two reviewers used the risk of bias (ROB) tool recommended by the Cochrane Handbook to evaluate included trials, and there was good agreement between reviewers. Not all RCTs provided the information on subsequent allocation; thus, all 7 trials were rated as having unclear risk of bias in this domain. Three RCTs comparing acupuncture to medicine did not provide adequate blinding information, and we believe this methodological limitation may potentially affect the findings. As a result, these 3 trials were rated as having a high risk of bias in this domain.22,26,28 Two RCTs provided the total NIH-CPSI score without subscores and did not report adverse events or drop offs; we thus figured there was a risk of incomplete outcome data and selective outcome reporting between the 2 trials.25,26 One RCT with a small group size (n = 36, 3 groups) was rated as high risk in other sources of bias domain.23 (See Table 4, http://links.lww.com/MD/A772 Supplemental Content, which represents the ROB of included RCTs).
Acupuncture Versus Sham Acupuncture
- NIH-CPSI total score: Sham acupuncture involves choosing nonacupoints (superficial and/or 10–15 mm to the left of each correct acupoint). Four RCTs involving 261 participants comparing acupuncture to sham acupuncture reported changes in the total NIH-CPSI score. Meta-analysis of 4 trials yielded a significant difference in favor of acupuncture (MD: −6.09 [95%CI: −8.12 to −5.68]) with moderate heterogeneity (I2 = 59%).23,24,27,28 (Figure 2)
- NIH-CPSI pain domain subscore: 4 RCTs involving 261 participants compared acupuncture to sham acupuncture. In the pain domain score, meta-analysis showed an average pain score reduction of 2.95 points (MD: −2.95 [95%CI: −5.05 to −0.85]) with high heterogeneity (I2 = 89%) (Figure 3). A sensitivity analysis succeeded in identifying the source of heterogeneity: 1 trial conducted by Zhao and Sun. After eliminating this trial from data combining, the heterogeneity vanished and could be accepted (I2 = 12%) with an average pain reduction of 1.95 (MD: −1.95 [95%CI: −2.71 to −1.19]).23,24,27,28 (See Figure 1, http://links.lww.com/MD/A772 Supplemental Content, which illustrates the sensitivity analysis.)
- NIH-CPSI voiding domain subscore: 4 RCTs involving 261 participants that compared acupuncture to sham acupuncture found an average reduction of 1.31 points in the NIH-CPSI voiding score. Meta-analysis showed a significantly greater improvement for acupuncture over sham acupuncture (MD: −1.31 [95%CI: −1.68 to −0.95]) with low heterogeneity (I2 = 2%)23,24,27,28 (Figure 4).
- NIH-CPSI quality of life domain subscore: for improvement in quality of life, the result of meta-analysis of 4 trials involving 261 participants indicated that compared with sham acupuncture, real acupuncture could improve the quality of life in patients with CP/CPPS (MD: −0.88 [95%CI: −1.20 to −0.56]) with moderated heterogeneity (I2 = 33%)23,24,27,28 (Figure 5).
- IPSS score: 2 trials involving 113 participants evaluated total IPSS score as a secondary outcome. In the results of meta-analysis, no significant differences were found among the treatment group (MD: −1.78 [95%CI: −4.30 to 0.75]) with I2 = 0%23,24 (Figure 6).
- Global response rate: 3 trials involving 129 participants reported global assessment as one of the outcomes. According to these trials, a participant who has a more than a 6-point decrease in total NIH-CPSI score after treatment can be considered a responder. A meta-analysis of the data showed favorable effects of acupuncture on improving the global assessment (RR: 1.60 [95%CI: 1.26 to 2.04]) with low heterogeneity (I2 = 14%)23,24,27 (Figure 7).
- Long-term follow-up response: 2 trials involving 180 participants observed long-term effects by measuring the changes in the total NIH-CPSI score after follow-up. One of the trials reported the NIH-CPSI subscale score after follow-up as well. After combining data, the result showed a significant difference in favor of acupuncture over sham acupuncture after 20 more weeks of follow-up (MD: −5.25 [95%CI: −10.40 to −0.1]) with a high heterogeneity of I2 = 89%. Because of the insufficient studies included, subgroup analyses or sensitivity analyses failed to explore the source of heterogeneity. As a result, the evidence of combing data has been limited. The source of heterogeneity may relate to different follow-up periods and the number of acupoints selected24,27 (Figure 8).
Acupuncture Versus Medication
- NIH-CPSI total score: 3 trials involving 177 participants that compared acupuncture to medication (Alfuzosin, Tamsulosin, and Prostat) reported the total NIH-CPSI score as the primary outcome and found an average reduction of 6.96 points (MD: −6.96 [95%CI: −12.05 to −1.87]) with high heterogeneity (I2 = 90%)22,25,28 (Figure 9). To identify the source of heterogeneity, sensitivity analyses were conducted. We determined the source of heterogeneity to be the RCT conducted by Liu et al.25 The unique form of acupuncture manipulation administered in this study may be the cause of the notably positive outcome. The trial used a sort of acupuncture manipulation called “Shuang Gu Yi Tong” and selected acupoints distributed on the head. After eliminating this study the I2 value decreased to 53% with the combined effect size (MD: −4.57 [95%CI: −7.58 to −1.56]).22,28 (See Figure 2, http://links.lww.com/MD/A772 Supplemental Content, which illustrates the sensitivity analysis.)
- NIH-CPSI pain domain subscore: 2 trials involving 112 participants compared acupuncture to medicine (Levofloxacinand and Tamsulosin) in terms of pain symptoms by measuring the NIH-CPSI pain domain subscore. The result of meta-analysis indicated that acupuncture is more effective than medication (MD: −3.20 [95%CI: −4.43 to −1.98]) with I2 = 0%22,28 (Figure 10).
- NIH-CPSI voiding domain subscore: 2 trials involving 112 participants compared acupuncture to medication (Levofloxacinand and Tamsulosin). The result was that acupuncture is not significantly different from medication (MD: 0.26 [95%CI: −2.03 to 2.56]) with high heterogeneity (I2 = 93%). Because there were insufficient RCTs included, subgroup analyses and sensitivity analyses failed to identify the source of heterogeneity22,28 (Figure 11).
- NIH-CPSI quality of life domain subscore: 2 trials involving 112 participants compared acupuncture to medication (Levofloxacinand and Tamsulosin). The results of meta-analysis showed that acupuncture did not have a significant effect (MD: −0.79 [95%CI: −1.58 to 0.00]) with an I2 value of 0%22,28 (Figure 12).
- Global assessment: 2 trials involving 98 participants evaluated acupuncture and medicine (Levofloxacinand and Prostat) for a global assessment. After combing data, the result indicated that patients treated with medication failed to report an improvement in their symptoms more frequently than patients treated with acupuncture (RR: 1.43 [95%CI: 1.08–1.90]) with moderate heterogeneity (I2 = 51%)22,25 (Figure 13).
Acupuncture Plus Medication Versus the Same Medication
NIH-CPSI total score and subscores: a single trial published in Chinese and including 60 participants was rated as having a high risk of bias; it compared acupuncture plus terazosin hydrochloride to administering terazosin hydrochloride alone.26 The use of Terazosin in the 2 groups was the same. The result showed that compared to terazosin alone, acupuncture plus terazosin had a greater effect on decreasing the total NIH-CPSI score (MD: −4.40 [95%CI: −6.85 to −1.95]). Meanwhile, it concluded that patients who received acupuncture plus terazosin experienced significant pain relief (MD: −2.66 [95%CI: −4.19 to −1.13]) and quality of life improvement (MD: −1.87 [95%CI: −2.78 to −0.96]). The urinary symptom score was negative (MD: −0.13 [95%CI: −1.02 to 1.28]).
One of the 7 trials reported on the occurrence of adverse events (ADs) in the acupuncture group;24 2 trials reported no ADs,22,27 and other trials did not provide information related to ADs.25,26,28 Overall, 1 trial calculated for ADs in all (6 hematomas, 2 with pain at needling sites).24,32
Summary of Findings
This systematic review was conducted to provide an update to prior reviews of acupuncture for CP/CPPS. So far, acupuncture has been used for management of symptoms in patients with CP/CPPS in many countries. Although the reported data came from uncontrolled series trials, the results suggested that acupuncture might provide benefits for relieving the symptoms of this syndrome.29–32 Due to the poorly understood etiology and pathology of this syndrome, symptom control is increasingly recognized as an important goal for patients with CP/CPPS, according to a systematic review aiming to assess all trials reporting on therapeutic intervention for CP/CPPS using the NIH-CPSI.21 Results showed that many current treatments for CP/CPPS are largely ineffective, including alpha-blockers and antibiotics. Acupuncture was found to produce statistically and clinically significant reductions in the NIH-CPSI voiding domain, but due to the insufficient number of trials, further research is needed to explore the use of acupuncture for CP/CPPS.33 In this review, we included RCTs comparing acupuncture to sham acupuncture or to conventional Western medicine and conducted meta-analysis to assess the effectiveness and safety of acupuncture for CP/CPPS.
On the basis of our analysis of 7 RCTs, we found that the current level of evidence supports the benefits of using acupuncture to improve symptoms in CP/CPPS patients, especially in the pain relief domain. Four trials examined acupuncture compared to sham acupuncture in terms of decreasing NIH-CPSI and reported positive outcomes; 2 of them were rated as having unclear risk of bias,24,27 whereas the other 2 trials were rated as high.23,25 To explore the efficacy of acupuncture, we combined the data among the trials and calculated the mean difference by comparing the outcomes of the sham acupuncture arm between baseline and endpoint after treatment. According to a consensus of expert opinion and data from a multicentre trial, a 6-point decrease in the total NIH-CPSI score between study completion and baseline can be seen as a minimum clinically important difference (MCID).10 The result of the meta-analysis showed the MD of change in total NIH-CPSI score is −6.09. This suggests that there are specific effects associated with acupuncture, at least over the short term. Two trials compared acupuncture to sham acupuncture, and the result of combing data was observed with high heterogeneity, which indicated that acupuncture may have long-term effects, but the evidence was limited. The between-group effect size estimates were insignificant among several trials, which suggested that nonspecific factors might have an impact on the treatment, yet the specific effects are greater. Another result of the meta-analysis, including 2 trials that focused on IPSS, conflicted with previous results by demonstrating that sham acupuncture was as effective as acupuncture in controlling urinary symptoms (as observed in the IPSS score).23,24 The contradicting sources are difficult to determine because neither subgroup analysis nor sensitivity analysis can be conducted with no other trials providing available information. We list our own theories herein. First, there was a different set of questions designed in the 2 questionnaires, despite the fact that 2 questionnaires can be used to quantitatively evaluate the severity of symptoms and both of them are excellent choices for evaluating the effectiveness of treatments. However, NIH-CPSI aimed to evaluate symptoms of CP/CPPS, and IPSS was designed for benign prostatic hypertrophy. We estimate that the design of the scales themselves might lead to this diversity. Second, the inadequate number of RCTs included, as well as the insufficient sample size, might also explain the conflicting results. Further studies are needed to explore the different evaluation effects between the NIH-CPSI voiding domain subscale and the IPSS scale.
In pharmaceutical controlled research, due to insufficient RCTs included to compare acupuncture to medicine and also because each trial administered a different sort of medicine (NSAIDs, alpha-blockers or antibiotics), the results of data combing showed significant heterogeneity, which makes the interpretation of findings difficult. Results showed that compared to medicine, acupuncture leads to a significant decrease in the total NIH-CPSI score and pain symptom subscale score; in terms of urinary symptoms and quality of life improvement, acupuncture was as effective as medicine. Because the included trials involving medicine as a control treatment were insufficient, it is difficult for investigators to perform subgroup analysis or sensitivity analysis. The heterogeneity in meta-analysis of voiding symptoms was observed to be high, and we believe the explanation is the different medication administered (including usage, dose, and treatment sessions) in each trial. One trial published in Chinese reported positive outcomes but was rated as having unclear risk of bias; it found that acupuncture plus medicine (terazosin hydrochloride) is superior to that particular medicine alone. This trial emphasizes that complementary use of acupuncture for symptom control in CP/CPPS is important to consider.
There are several possible interpretations of these findings caused by a mixture of different types of interventions and treatment sessions. Compared with medicine, acupuncture is effective and safe for patients with CP/CPPS in terms of decreasing the total NIH-CPSI score, particularly in pain relief. With regard to the voiding domain and quality of life domain, acupuncture is more effective than sham acupuncture (inserting a needle into sham acupoints) and may be as effective as medicine. In addition, acupuncture may be more effective as a complement to medicine than medication alone.
Comparisons With Previous Study
In 2012, a systematic review that included 9 Asian RCTs was published and concluded that acupuncture is an encouraging therapy for CP/CPPS.15 We sought to identify all relevant trials in the previous review. Given our rigorous criteria, most of the included trials published in Chinese were unavailable for data abstraction, as they did not provide adequate information related to the characteristics of participants as well as outcome measures. Posadzki et al noted that the quantity and the quality of existing evidence is also insufficient to draw firm conclusions. Moreover, this review included global assessment as an outcome measure. However, as mentioned above, most relevant trials included in this review did not describe detailed information about outcomes. As a result, conclusions are limited. On the other hand, due to the quantity and quality of the included trials, the authors of the previous systematic review did not conduct a meta-analysis of NIH-CPSI total score, nor did they do so for subscale score or any other measures. In terms of interventions, it included insufficient trials comparing acupuncture with sham acupuncture. Thus, it is difficult to combine the data. Furthermore, no follow-up data has been collected for the previous systematic review. Hence, evaluation of the long-term effects of acupuncture was unsuccessful. In this systematic review, we formulated rigorous standards for including RCTs to guarantee the quality of evidence. We also extracted data from graded uniform outcome measurements that have been widely accepted (NIH-CPSI) to provide generalized evidence using quantity analysis.
This review has several limitations that should be addressed. First, although every study provided before-and-after treatment data, only 2 of them had the change in value as a primary outcome. Therefore, to calculate the difference of mean as well as the standard deviation, we estimated the missing data by assuming the correlation coefficient R was 0.5, a conservative value that leads to the highest variance. Second, the mixture of different types of acupuncture, frequency of administration, duration of each session, and location of acupoints may have a potential impact on the effects of acupuncture. However, because the included trials were insufficient, it is difficult to conduct subgroup analysis or meta-regression to avoid this methodological limitation. All of the trials lacked the details of concealment and most of them did not provide adequate information on blinding either. Because of the characteristic of acupuncture, it is difficult to conduct blinding in patients, especially the trial that included a control group with drugs administered. However, for acupuncture, blinding to assessors is one of the cardinal methods to enable the generalizability of findings. Moreover, due to the lack of reporting on placebo-controlled trials that compare acupuncture to nonpenetrated acupuncture, placebo effects are impossible to eliminate. The specific effects of acupuncture needling are not well understood.
In conclusion, the evidence supported acupuncture as an effective treatment to improve symptoms of CP/CPPS. Compared with sham acupuncture, real acupuncture leads to significant reductions in the pain, urinary symptoms, and quality of life domains of the NIH-CPSI. Compared with conventional Western medicine, acupuncture may be more effective in decreasing the total NIH-CPSI score, especially in terms of pain relief. With regard to urinary symptoms and quality of life, there is no significant difference between acupuncture and conventional Western medicine. Current existing evidence allows limited conclusions to be reached through comparing acupuncture and medicine, and additional trials are needed to improve the reliability of these findings. In terms of adverse events, acupuncture was linked to rare and slightly adverse events such as hematomas or pain, but these resolved quickly and no other serious events have been reported. In addition, the use of acupuncture as an appropriate adjunctive treatment for symptom control in patients with CP/CPPS should be considered.
1. Rees J, Abrahams M, Doble A, et al. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int
2. Marszalek M, Wehrberger C, Hochreiter W, et al. Symptoms suggestive of chronic pelvic pain syndrome in an urban population: prevalence and associations with lower urinary tract symptoms and erectile function. J Urol
3. Tripp DA, Nickel JC, Wang Y, et al. Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome. J Pain
4. Walz J, Perrotte P, Hutterer G, et al. Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. BJU Int
5. Liang CZ, Li HJ, Wang ZP, et al. The prevalence of prostatitis-like symptoms in China. J Urol
6. Mahal BA, Cohen JM, Allsop SA, et al. The role of phenotyping in chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep
7. Alexander RB, Propert KJ, Schaeffer AJ, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Int Med
8. Giannantoni A, Porena M, Gubbiotti M, et al. The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology
9. Lee CB, Ha US, Lee SJ, et al. Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World J Urol
10. Nickel JC, Narayan P, McKay J, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol
11. Nickel JC, Pontari M, Moon T, et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol
12. Nickel JC, Shoskes DA. Phenotypic approach to the management of the chronic prostatitis/chronic pelvic pain syndrome. BJU Int
13. Shoskes DA, Nickel JC, Rackley RR, et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis
14. Blanchet KD. Acupuncture: gaining acceptance in urology: proves effective for a number of chronic conditions. BJU Int
15. Posadzki P, Zhang J, Lee MS, et al. Acupuncture for chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a systematic review. J Androl
16. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ
17. Litwin MS, McNaughton-Collins M, Fowler FJ, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol
18. Litwin MS. A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. Urology
2002; 60 (6 Suppl):14–18.discussion 18–19.
19. Higgins J GS. Cochrane handbook for systematic reviews of interventions v.5.1.0. Updated March 2011. Cochrane Web site. Cochrane Web site http://handbookcochraneorg/2011
20. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ
21. Liu Y, Yang S, Dai J, et al. Risk of bias tool in systematic reviews/meta-analyses of acupuncture in Chinese journals. PloS One
22. Kucuk EV, Suceken FY, Bindayi A, et al. Effectiveness of acupuncture on chronic prostatitis-chronic pelvic pain syndrome category IIIB patients: a prospective, randomized, nonblinded, clinical trial. Urology
23. Lee SH, Lee BC. Electroacupuncture relieves pain in men with chronic prostatitis/chronic pelvic pain syndrome: three-arm randomized trial. Urology
24. Lee SW, Liong ML, Yuen KH, et al. Acupuncture versus sham acupuncture for chronic prostatitis/chronic pelvic pain. Am J Med
2008; 121: 79 e71-77.
25. Liu JM, Huang GF, Li HT, et al. Clinical observation of “Shuang Gu Yi Tong” acupuncture for chronic prostatitis accompany with depression (Chinese). Guide of China Medicine
26. Qi YL, Wu WZ. Effect of acupuncture on cytokine in patients with chronic nonbacterial prostatitis (Chinese). Shandong J Tradit Chin Med
27. Sahin S, Bicer M, Eren GA, et al. Acupuncture relieves symptoms in chronic prostatitis/chronic pelvic pain syndrome: a randomized, sham-controlled trial. Prostate Cancer Prostatic Dis
28. Zhao JY, Sun C. Clinical observation of Jiao Xue acupuncture treatment on IIIB prostatitis (Chinese). Chin J Hum Sexuality
29. Capodice JL, Jin Z, Bemis DL, et al. A pilot study on acupuncture for lower urinary tract symptoms related to chronic prostatitis/chronic pelvic pain. Chin Med
30. Chen R, Nickel JC. Acupuncture ameliorates symptoms in men with chronic prostatitis/chronic pelvic pain syndrome. Urology
2003; 61:1156–1159.discussion 1159.
31. Honjo H, Kamoi K, Naya Y, et al. Effects of acupuncture for chronic pelvic pain syndrome with intrapelvic venous congestion: preliminary results. Int J Urol
32. Tugcu V, Tas S, Eren G, et al. Effectiveness of acupuncture in patients with category IIIB chronic pelvic pain syndrome: a report of 97 patients. Pain Med
33. Cohen JM, Fagin AP, Hariton E, et al. Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis. PloS One
Supplemental Digital Content
Copyright © 2016 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.